Navigation Links
COMBACTE: A new step in the fight against resistance to antibiotics
Date:2/26/2013

The COMBACTE (Combatting Bacterial Resistance in Europe) project, resulting from the sixth Call for proposals issued by the IMI, is one of the projects that is part of the "New Drugs For Bad Bugs" (ND4BB) programme. It is the result of the initial association between industry and two academic consortia, the Eu-ACT and INCRAID, run respectively by Marc Bonten of the University of Utrecht and Bruno Franois of Limoges University Hospital, both being responsible for overall project coordination along with representatives of the EFPIA, Scott White (GlaxoSmithKline) and Seamus O'Brien (Astra Zeneca).

The project will last for seven years and will bring together about 20 partners from all over Europe. It is designed to generate innovative trials to facilitate the registration of new anti-bacterial agents, mainly through the creation of a network of experienced investigators. It will also design and validate tests to support the diagnosis of patients, identify the most suitable treatments and monitor the treatment response.

Much of the project will be devoted to performing clinical trials of anti-infectious medication currently being developed by the pharmaceutical companies involved in the programme. The first antibiotic to be subjected to clinical trials under the COMBACTE programme has been developed by GlaxoSmithKline's laboratories.

For these purposes, the total budget for the COMBACTE project amounts to nearly 195 million euros, a scale of finance hitherto unequalled in private-public clinical research.

French partners in the European COMBACTE Project

Of the various partners, several French entities are involved in the COMBACTE project.

Dr Bruno Franois, under the aegis of Limoges University Hospital, will be responsible for coordinating the clinical trials in collaboration with all the European investigator centres and the GSK Group and GSK France (GSK Medical Management France) Research Groups. Dr Franois will also participate in the overall project management.

INSERM and its Midi-Pyrnes/Limousin directorate headed by Armelle Barelli will be responsible for budget management for all the project's clinical trials.

ECRIN (European Clinical Research Infrastructures Network) coordinated by INSERM and headed by Professor Jacques Demotes, is an infrastructure whose purpose is to facilitate the setting up of international trials in Europe. ECRIN will be responsible for the management of the project's clinical trials through its European partners, ensuring coordination between the various national networks.

Dr Laurent Abel (INSERM U980 "Human genetics of infectious diseases"), another French member of the consortium, will participate in the identification in humans of genetic markers affecting the susceptibility/resistance to bacterial infection and the response to their treatment, along with the other partners.

Two French networks will also participate in clinical trials for the COMBACTE project, the Rseau National de Recherche Clinique en Infectiologie (RENARCI) coordinated by Professor Bruno Hoen (Besanon University Hospital), with the support of the Institut Thmatique Multi-Organismes "Microbiologie et Maladies Infectieuses" (IMMI) directed by Professor Jean-Franois Delfraissy, and the CRICS (Clinical Research in Intensive Care and Sepsis) network, headed by Dr Bruno Franois and Professor Pierre-Franois Dequin at the Tours University Hospital. The Groupe pour la Recherche et l'Enseignement en Pneumo-Infectiologie (a Working Party emanating from the Socit de Pneumologie de Langue Franaise) coordinated by Professor Anne Bergeron at the AP-HP Saint-Louis with the collaboration of Dr Muriel Fartoukh at the APHP Tenon will be associated with the CRICS network.

COMBACTE, a unique excellence project with international visibility

COMBACTE is the European public/private partnership set up for the development of drugs.

The development of new antibiotics represents a challenge that justifies the association of several of the major players. By bringing together experts in the various fields (research bodies, universities, hospitals and the pharmaceutical industries) specialising in microbiology, epidemiology, the development of drugs and clinical trials, the aim of COMBACTE is to improve and accelerate the development of antibiotics.

Unique in its scale, ambitious, with benefits that can be expected for patients, public health and research in Europe, COMBACTE has the potential to become the leading light in Europe in the antimicrobial drug development.


'/>"/>

Contact: Elodie PFENDER
elodie.pfender@chu-limoges.fr
33-055-505-8837
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related biology news :

1. Scientists find bone-marrow environment that helps produce infection-fighting T and B cells
2. Compound stimulates tumor-fighting protein in cancer therapy
3. In a fight to the finish, Saint Louis University research aims knockout punch at hepatitis B
4. Planning for bacteria in cancer patients may help hospitals fight infections
5. La Jolla Institute identifies molecular switch enabling immune cells to better fight disease
6. New insights into how immune system fights atherosclerosis
7. University of Tennessee researchers find fungus has cancer-fighting power
8. Compound in grapes, red wine could be key to fighting prostate cancer
9. Immune system fighters speak in patterns of proteins, prefer squishy partners
10. Fighting melanomas attraction to the brain
11. An important breakthrough in the fight against muscular dystrophies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:2/28/2017)... ANGELES , Feb. 28, 2017   Acuant ... verification software globally, announces significant enhancements to new and ... May 2016. New products include mobile and desktop Acuant ... DocX TM - a real time manual review ... core idScanĀ® technology provides the fastest and most accurate ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... ... ... Benchworks CEO Thad L. Bench Sr. will participate in the ... San Diego. The event is a gathering of executive leadership from companies in the ... Meyer will also participate in the forum. Participants will discuss the future of the ...
Breaking Biology Technology: